RT Journal Article
T1 Development of an Inverted Epifluorescence Microscope for Long-Term Monitoring of Bacteria in Multiplexed Microfluidic Devices
A1 Torres Simón, Amaro
A1 Marino Miguélez, María Henar
A1 Gómez Cruz, Clara
A1 Cañadas Ortega, Marina
A1 Marco Esteban, Miguel
A1 Ripoll Lorenzo, Jorge
A1 Vaquero López, Juan José
A1 Muñoz Barrutia, María Arrate
AB Developing more efficient methods for antibiotic susceptibility testing is a pressing issuein novel drug development as bacterial resistance to antibiotics becomes increasingly common.Microfluidic devices have been demonstrated to be powerful platforms that allow researchers toperform multiplexed antibiotic testing. However, the level of multiplexing within microdevicesis limited, evidencing the need of creating simple, low-cost and high-resolution imaging systemsthat can be integrated in antibiotic development pipelines. This paper describes the design anddevelopment of an epifluorescence inverted microscope that enables long-term monitoring of bacteriainside multiplexed microfluidic devices. The goal of this work is to provide a simple microscopepowerful enough to allow single-cell analysis of bacteria at a reduced cost. This facilitates increasingthe number of microscopes that are simultaneously used for antibiotic testing. We prove that thedesigned system is able to accurately detect fluorescent beads of 100 nm, demonstrating comparablefeatures to high-end commercial microscopes and effectively achieving the resolution required forsingle-cell analysis of bacteria. The proposed microscope could thus increase the efficiency in antibiotictesting while reducing cost, size, weight, and power requirements, contributing to the successfuldevelopment of new antibiotic drugs.
PB MDPI
SN 1424-8220
YR 2020
FD 2020-08-01
LK https://hdl.handle.net/10016/32946
UL https://hdl.handle.net/10016/32946
LA eng
NO This work was partially funded by project TEC2016-78052-R from the Spanish Ministry of Economy and PID2019-109820RB-I00 from the Spanish Ministry of Science and Innovation. The research leading to these results received funding from the Innovative Medicines Innitiative 2 Joint Undertaking (JU) under grant agreement No 853989. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Global Alliance for TB Drug Development non profit organisation, Bill & Melinda Gates Foundation and University of Dundee.
DS e-Archivo
RD 1 sept. 2024